[Federal Register: August 3, 2005 (Volume 70, Number 148)]
[Notices]
[Page 44662]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03au05-162]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
National Mammography Quality Assurance Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: National Mammography Quality Assurance Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 26 and 27,
2005, from 9 a.m. to 6 p.m.
Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery
Village Ave., Gaithersburg, MD.
Contact Person: Charles Finder, Center for Devices and Radiological
Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr.,
Rockville, MD 20850, 301-594-3332, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 3014512397. Please call the Information Line for up-to-date
information on this meeting.
Agenda: The committee will discuss the following issues:
(1) Regulatory and nonregulatory mechanisms to enhance mammography
quality while reducing the regulatory and inspection burden on
facilities;
(2) Recommendations made by the Institute of Medicine regarding the
current Mammography Quality Standards Act (MQSA) program,
interventional mammography, and nonmammographic breast imaging
procedures; and
(3) All relevant guidance documents issued since the last meeting.
The committee will also receive updates on recently approved
alternative standards, voluntary stereotactic accreditation programs,
and the radiological health program. MQSA regulations and guidance
documents are available to the public on the Internet at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/cdrh/mammography
.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by September 5,
2005. Oral presentations from the public will be scheduled between
approximately 9:30 a.m. and 10:30 a.m. on both days. Time allotted for
each presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before September 5,
2005, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Shirley Meeks at
240-276-0450, ext. 105, at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: July 27, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-15373 Filed 8-2-05; 8:45 am]
BILLING CODE 4160-01-S